Effect Evaluation of Strychnos nux-vomica L.with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients:A Self-Controlled Clinical Trial  

作　　者：DAI Tie-ying CHEN Chu-chu HONG Li-li Ge Hang-ping PEI Jun LYU Wen-qi YANG Xue SHEN Jian-ping HU Zhi-ping 

机构地区：[1]Department of Hematology,the First Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine,Hangzhou(310006),China

出　　处：《Chinese Journal of Integrative Medicine》2021年第2期131-136,共6页中国结合医学杂志（英文版）

基　　金：Supported by Zhejiang Province Traditional Chinese Medicine Scientific Research Fund Project(No.2015ZA094)。

摘　　要：Objective:To explore the clinical effect and adverse reactions of Strychnos nux-vomica in bortezomib-induced peripheral neuropathy(BIPN)of patients with multiple myeloma(MM).Methods:A total of 19 MM patients with BIPN were enrolled and Nux Vomica Capsule(NVC,0.4 g,thrice daily)were orally administrated for 30 days.Comparative analysis on parameters between pre-and post-therapy,including peripheral neuropathy(PN)grade,neurotoxicity score,Chinese medicine(CM)syndrome score,total neuropathy score(TNS),coagulation function,and serum nerve growth factor(NGF)levels were conducted.The adverse events were monitored.Results:In BIPN of MM patients who received NVC,PN grade was lowered,neurotoxicity score was obviously decreased(P 0.01),and both CM syndrome score and TNS were remarkably decreased(P<0.01).After the therapy,activated partial thromboplastin time was prolonged(P<0.01)and fibrinogen was declined(P<0.05),showing improvement in the hypercoagulable state of patients.No significant difference of NGF recovery degrees was detected between pre-and post-therapy(P>0.05).No evident adverse reactions were observed during the course of treatment.Conclusion:Strychnos nux-vomica L.has significantly effect with a good safety in treatment of BIPN in MM patients.

关 键 词：bortezomib-induced peripheral neuropathy grilled nux vomica total neuropathy score Chinese medicine syndrome score nerve growth factor 

分 类 号：R733.3[医药卫生—肿瘤]